Michael Baine, MD, PhD, is a physician-scientist in the Department of Radiation Oncology at the University of Nebraska Medical Center, where he acts as a treating radiation oncologist and brachytherapist. His clinical work focuses primarily on genitourinary malignancies, particularly prostate and bladder cancers. Dr. Baine’s research is focused on improving diagnosis, the ability to provide a meaningful prognosis, and radiation-based outcomes in patients.
Dr. Baine earned his MD and PhD at the University of Nebraska Medical Center. He remained there for an internship in internal medicine followed by a residency in radiation oncology, from which he graduated in 2019.
Dr. Nadine J. Barrett is a medical sociologist and an assistant professor in the Department of Community and Family Medicine, within Duke University’s School of Medicine. She is the inaugural director of the Office of Health Equity and Disparities at the Duke Cancer Institute and serves as the director of the Duke Community Engagement Core, within the Center for Community and Population Health Improvement. A health equity and stakeholder engagement strategist, Dr. Barrett applies her expertise across three interrelated areas: 1) linking vulnerable communities to health services and research, 2) leveraging community and health system assets and services to align priorities and improve community and population health, and 3) convening diverse stakeholders to develop community and patient-centered programs, services, and research.
In 2017, she accepted an ACCC Innovator Award on behalf of Duke Cancer Institute for its initiative, Come Together: A Health Disparities & Equity Cancer Program Built on Community Collaboration. She is the recipient of several awards, including the American Sociology Association’s Minority Fellowship Award, an NIH Postdoctoral Fellowship in Health Services Research, and the MLK Southern Christian Leadership Conference Drum Major for Justice Award. Her national appointments include the PCORI Health Disparities Advisory Panel Board and the ACCC Board of Trustees. Dr. Barrett is both passionate about and committed to achieving health equity.
Dr. Barrett has several funded projects including Project PLACE (Population Level Approaches to Cancer Elimination), funded by the National Cancer Institute (NCI), which is a three-pronged research project designed to implement three robust mechanisms to inform the health equity strategic direction of the Duke Cancer Institute over the next five to eight years. Project PLACE is a highly intensive community engagement model and platform designed to shape robust scholarly productivity, partnered research and community programs to improve population health. She is also the Duke PI (subcontract) of a national Susan G. Komen pipeline training grant on translational research in inflammatory breast cancer and community-engaged research. Dr. Barrett also co-directs the NCI-funded Cancer Research and Education Program Core of the NCCU/DCI Translational Health Disparities Research Program which incorporates specified training in minority accrual in clinical research—a program she developed within the Duke Cancer Institute titled, “Just Ask.”
Frank dela Rama, RN, MS, AOCNS, AGN-BC, is the prostate cancer nurse navigator at the Palo Alto Medical Foundation (PAMF). He created the cancer genetics program at PAMF, which provides genetic counseling and testing, predominantly for BRCA1/2 genes (hereditary breast/ovarian cancer syndrome) and Lynch Syndrome genes (hereditary colorectal cancer). Dela Rama has developed multiple programs and services at PAMF, including a survivorship program, oncology nurse navigator program, the Prostate Cancer Buddy Program, and studies in cancer treatment decision-making strategies. He is on the editorial board of several oncology nursing publications.
Frank earned his master’s degree from the University of California, San Francisco to become an advanced oncology clinical nurse specialist (AOCNS) in oncology/genomics.
Heather Honoré Goltz, PhD, LCSW, MEd, is a tenured associate professor of social work at the University of Houston-Downtown and holds a research appointment with the Michael E. DeBakey VAMC. She is a licensed clinical social worker and doctoral-level health educator with more than a decade of experience developing and implementing clinical interventions to improve the quality of life and health outcomes of patients, caregivers, and couples impacted by complex medical and behavioral health conditions. Dr. Goltz has co-authored more than 30 peer-reviewed articles and collaborated on projects funded by nearly $3 million in research grants from the ACS, NIH, DOD, and VA, primarily focusing on genitourinary cancer survivorship and sexual health.
David M. Latini, PhD, MSW, is an associate professor of urology at the Baylor College of Medicine. He is a clinical psychologist and oncology social worker focusing on the quality of life and symptom management of bladder and prostate cancer survivors. Dr. Latini’s work has a strong emphasis on improving access to cancer survivorship care for underserved groups, particularly persons with low health literacy and members of the LGBT community. Dr. Latini’s work has been funded to develop and evaluate a symptom management patient education program for low-literacy men who are being treated for localized prostate cancer. He and his colleagues on the BCAN Survivorship Working Group recently published their work describing the first bladder cancer survivorship care plan.
Dr. Latini’s work has been funded by the National Cancer Institute, National Institute of Mental Health, American Cancer Society, Department of Defense Congressionally Directed Medical Research Program, Baylor College of Medicine, Mt. Zion Health Fund, and the pharmaceutical industry.
Nynikka Palmer, MPH, DrPH, is an assistant professor of medicine at the University of California San Francisco, with secondary appointments in the Departments of Urology and Radiation Oncology. As a mixed-methods public health researcher, Dr. Palmer is committed to unraveling cancer disparities by using community engagement, relationship-centered communication, and multilevel strategies to enhance the delivery of high-quality cancer care. Dr. Palmer has been funded by the National Cancer Institute to work to enable low-income African American men to access high-quality prostate cancer treatment. She seeks to do this by anchoring the evidence-based intervention of peer navigation in the relational concept of African American brotherhood to foster trust and empowerment and optimize patient-centered communication, treatment decision-making, and quality of care.
Dr. Palmer is the co-leader of the Prostate Cancer Task Force of the San Francisco Cancer Initiative, which works to eliminate prostate cancer disparities through community engagement and education, targeted early detection, appropriate follow-up of aggressive disease, navigation and support services, and institutional partnerships that ensure high-quality care city-wide. Dr. Palmer is also on the Board of Directors for the Academy of Communication in Healthcare, as the Expert in Communication Research to Promote Health Equity.
Edith Peterson Mitchell, MD, MACP, FCPP, has spent her medical career helping individuals in medically underserved areas realize that simple changes in lifestyle can have a dramatic impact on cancer care. Through her work, Dr. Mitchell has demonstrated the importance of community service and outreach, especially to individuals who may not have the means to seek out more conventional medical advice.
Dr. Mitchell’s research in breast, colorectal, and pancreatic cancers and other GI malignancies involves new drug evaluation and chemotherapy, development of new therapeutic regimens, chemoradiation strategies for combined modality therapy, patient selection criteria, and supportive care for patients with gastrointestinal cancer.
Dr. Mitchell holds leadership positions in the American Society of Clinical Oncology and was the 116th President of the National Medical Association, serving from 2015-2016. She travels nationally and internationally teaching and lecturing on the treatment of gastrointestinal malignancies. She serves on the National Cancer Institute Review Panel, the Cancer Investigations Review Committee, and the Clinical Trials and Translational Research Advisory Committee. Dr. Michell is the co-chair of the NCI Disparities Committee, and she is a member of the NIH Council of Councils. She was selected to serve as a member of the NCI’s Blue Ribbon Panel convened to advise the National Cancer Advisory Board on Vice President Biden’s National Cancer Moonshot Initiative. In 2019, Dr. Mitchell began service as a member of the President’s Cancer Panel.
Samuel L. Washington III, MD, MAS, is an assistant professor of urology within the Department of Urology at UCSF. His primary research focus is healthcare disparities in patients with genitourinary malignancies, with specific interest in understanding racial/ethnic disparities in the diagnosis, management, and treatment of genitourinary cancers.
Dr. Washington finished his medical school training at the University of California, San Francisco, and he was matched with the Department of Urology to complete his urology residency. In 2018, he stayed on at UCSF to complete his urologic oncology fellowship and complete a master’s degree in clinical research. During his training at UCSF, Dr. Washington has received grants from the UCSF Academy of Medical Educators and the UCSF Center of Aging in Diverse Communities through the National Institute of Aging.
Evan Y. Yu, M.D., is a medical oncologist specializing in prostate, bladder, and testicular cancer treatment and research at both the Seattle Cancer Care Alliance (SCCA) and the University of Washington Medical Center (UWMC). He graduated Alpha Omega Alpha from the University of Washington School of Medicine. Dr. Yu is the Clinical Research Director for GU malignancies, Core Director for the Pacific Northwest Prostate Cancer SPORE and co-PI of the DoD Prostate Cancer Clinical Trials Consortium for his institution. He is the institutions Principal Investigator for the National Cancer Trials Network Lead Academic Performance Site (LAPS) Grant, SWOG, and ECOG/ACRIN. His research focuses on testing the next wave of novel molecular targeted therapies and immunotherapy techniques, with a complementary focus on imaging biomarkers. In addition to an active clinical and research practice, he also is the Medical Director for Clinical Research Services at the Fred Hutchinson Cancer Consortium. Previously, he served as a Hematology/Oncology Fellowship Program Director for a decade at the Fred Hutchinson Cancer Research Center. He has regularly been voted a “Top Doctor” by Castle Connolly, U.S. News and World Report, Seattle magazine, and Seattle Met magazine. He has served for many years on the National Cancer Institute Genitourinary Cancers Steering Committee and is the Co-Chair for the National Cancer Institute Prostate Cancer Task Force. Dr. Yu has held various roles within ASCO, AACR, and also serves as a senior editor for Clinical Cancer Research and Uro-Today.
James Hutson is an experienced educator with a demonstrated history of working in higher education and healthcare. As Development Director for Us TOO International, his focus is on raising awareness about and providing educational resources and support services to those affected by prostate cancer to help them learn to fight the disease. Currently, he is leading an effort to address health inequities in prostate cancer care.
Dr. Kendall earned his undergraduate degree from Indiana State University and completed his post-doctoral fellowship in psychosocial oncology at Roswell Park Cancer Institute in Buffalo, New York. For the past 23 years, Dr. Kendall has directed oncology supportive care departments within NCI-designated comprehensive cancer centers, academic medical centers, and community cancer centers. In 2016, he joined the University of Minnesota Cancer Care program, where he is dedicated to addressing the impact of cancer on individuals and families. Currently, Dr. Kendall’s professional time is divided among direct patient care, program administration, program development, and research collaboration. To raise awareness of the needs of cancer patients, Dr. Kendall speaks nationally and internationally, and he has published 40 journal articles and abstracts on topics related to psychosocial oncology and cancer survivorship. As a nationally recognized thought leader in his field, Dr. Kendall serves on committees for the American Psychosocial Oncology Society and the Association of Community Cancer Centers.
Shelby Moneer, MS, CHES, is the vice president of Patient Programs & Education at ZERO – The End of Prostate Cancer. She is a health education professional with more than 12 years of experience in the development, implementation, and assessment of patient education and awareness programming. Prior to joining ZERO, Shelby served as the director of Education at the Melanoma Research Foundation. In this role, she was responsible for all patient education and support programs as well as creating engaging website content, managing a vast portfolio of educational literature, and ensuring the patient voice remained at the center of the organization’s mission.
Shelby’s experience collaborating with health professionals and foundations has resulted in award-winning educational infographics, awareness campaigns, and digital health programs. She regularly works alongside industry partners and various healthcare stakeholders to develop literature, messaging, and resources that use evidence-based health literacy practices aimed at empowering patients to become active participants in their treatment and care.
Wendy serves as the President of the Prostate Conditions Education Council—a national nonprofit organization—and previously served as an administrator of a multidisciplinary urologic oncology clinic in a National Cancer Institute-designated cancer center.
Wendy has experience in medical education, teaching patients and healthcare professionals. She has also built patient advocacy programs and has overseen large clinical trials and research work. Her expertise and areas of interest include building knowledge on a multidisciplinary approach to healthcare, maximizing patient outcomes, and enhancing survivorship.
Funding and support provided by Pfizer Oncology.